Renal cancer treatment: A review of the literature

Luca Gattinoni, Massimiliano Alù, Leonardo Ferrari, Paola Nova, Michele Del Vecchio, Giuseppe Procopio, Agata Laudani, Biagio Agostara, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

Renal carcinoma represents about 3% of all adult tumors, with an estimate of 31,900 new cases diagnosed in 2003 in the United States. In the early phase of its natural history, renal cancer is potentially curable by surgery, but if the disease presents any signs of metastasis, the chances of survival are remote, even though anecdotal cases characterized by long survival have been reported. In fact, the treatment of metastatic renal cancer remains unsatisfactory. Systemic treatment with single agents and with polychemotherapy, with or without cytokine-based immunotherapy, has not been successful, obtaining very low response rates without a significant benefit in overall survival. This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease. New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed.

Original languageEnglish
Pages (from-to)476-484
Number of pages9
JournalTumori
Volume89
Issue number5
Publication statusPublished - Sep 2003

Fingerprint

Kidney Neoplasms
Active Immunotherapy
Angiogenesis Inhibitors
Cell Transplantation
Homologous Transplantation
Combination Drug Therapy
Natural History
Genetic Therapy
Immunotherapy
Therapeutics
Monoclonal Antibodies
Cytokines
Neoplasm Metastasis
Carcinoma
Kidney
Neoplasms

Keywords

  • Bio-immunotherapy
  • Chemotherapy
  • Renal cancer
  • Surgery

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gattinoni, L., Alù, M., Ferrari, L., Nova, P., Del Vecchio, M., Procopio, G., ... Bajetta, E. (2003). Renal cancer treatment: A review of the literature. Tumori, 89(5), 476-484.

Renal cancer treatment : A review of the literature. / Gattinoni, Luca; Alù, Massimiliano; Ferrari, Leonardo; Nova, Paola; Del Vecchio, Michele; Procopio, Giuseppe; Laudani, Agata; Agostara, Biagio; Bajetta, Emilio.

In: Tumori, Vol. 89, No. 5, 09.2003, p. 476-484.

Research output: Contribution to journalArticle

Gattinoni, L, Alù, M, Ferrari, L, Nova, P, Del Vecchio, M, Procopio, G, Laudani, A, Agostara, B & Bajetta, E 2003, 'Renal cancer treatment: A review of the literature', Tumori, vol. 89, no. 5, pp. 476-484.
Gattinoni L, Alù M, Ferrari L, Nova P, Del Vecchio M, Procopio G et al. Renal cancer treatment: A review of the literature. Tumori. 2003 Sep;89(5):476-484.
Gattinoni, Luca ; Alù, Massimiliano ; Ferrari, Leonardo ; Nova, Paola ; Del Vecchio, Michele ; Procopio, Giuseppe ; Laudani, Agata ; Agostara, Biagio ; Bajetta, Emilio. / Renal cancer treatment : A review of the literature. In: Tumori. 2003 ; Vol. 89, No. 5. pp. 476-484.
@article{059ae4da829241b6843be2390c4df5f2,
title = "Renal cancer treatment: A review of the literature",
abstract = "Renal carcinoma represents about 3{\%} of all adult tumors, with an estimate of 31,900 new cases diagnosed in 2003 in the United States. In the early phase of its natural history, renal cancer is potentially curable by surgery, but if the disease presents any signs of metastasis, the chances of survival are remote, even though anecdotal cases characterized by long survival have been reported. In fact, the treatment of metastatic renal cancer remains unsatisfactory. Systemic treatment with single agents and with polychemotherapy, with or without cytokine-based immunotherapy, has not been successful, obtaining very low response rates without a significant benefit in overall survival. This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease. New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed.",
keywords = "Bio-immunotherapy, Chemotherapy, Renal cancer, Surgery",
author = "Luca Gattinoni and Massimiliano Al{\`u} and Leonardo Ferrari and Paola Nova and {Del Vecchio}, Michele and Giuseppe Procopio and Agata Laudani and Biagio Agostara and Emilio Bajetta",
year = "2003",
month = "9",
language = "English",
volume = "89",
pages = "476--484",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Renal cancer treatment

T2 - A review of the literature

AU - Gattinoni, Luca

AU - Alù, Massimiliano

AU - Ferrari, Leonardo

AU - Nova, Paola

AU - Del Vecchio, Michele

AU - Procopio, Giuseppe

AU - Laudani, Agata

AU - Agostara, Biagio

AU - Bajetta, Emilio

PY - 2003/9

Y1 - 2003/9

N2 - Renal carcinoma represents about 3% of all adult tumors, with an estimate of 31,900 new cases diagnosed in 2003 in the United States. In the early phase of its natural history, renal cancer is potentially curable by surgery, but if the disease presents any signs of metastasis, the chances of survival are remote, even though anecdotal cases characterized by long survival have been reported. In fact, the treatment of metastatic renal cancer remains unsatisfactory. Systemic treatment with single agents and with polychemotherapy, with or without cytokine-based immunotherapy, has not been successful, obtaining very low response rates without a significant benefit in overall survival. This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease. New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed.

AB - Renal carcinoma represents about 3% of all adult tumors, with an estimate of 31,900 new cases diagnosed in 2003 in the United States. In the early phase of its natural history, renal cancer is potentially curable by surgery, but if the disease presents any signs of metastasis, the chances of survival are remote, even though anecdotal cases characterized by long survival have been reported. In fact, the treatment of metastatic renal cancer remains unsatisfactory. Systemic treatment with single agents and with polychemotherapy, with or without cytokine-based immunotherapy, has not been successful, obtaining very low response rates without a significant benefit in overall survival. This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease. New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed.

KW - Bio-immunotherapy

KW - Chemotherapy

KW - Renal cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0346996610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346996610&partnerID=8YFLogxK

M3 - Article

C2 - 14870767

AN - SCOPUS:0346996610

VL - 89

SP - 476

EP - 484

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -